Tudor G Jovin1, Gregory W Albers2, David S Liebeskind2. 1. From the Stroke Institute and UPMC Center for Neuroendovascular Therapy, Pittsburgh, PA (T.G.J.); Department of Neurology, University of Pittsburgh Medical Center, PA (T.G.J.); Department of Neurology, Stroke Center, Stanford University School of Medicine, Palo Alto, CA (G.W.A.); and Department of Neurology, Neurovascular Imaging Research Core, UCLA Stroke Center, University of California, Los Angeles (D.S.L.). jovintg@upmc.edu. 2. From the Stroke Institute and UPMC Center for Neuroendovascular Therapy, Pittsburgh, PA (T.G.J.); Department of Neurology, University of Pittsburgh Medical Center, PA (T.G.J.); Department of Neurology, Stroke Center, Stanford University School of Medicine, Palo Alto, CA (G.W.A.); and Department of Neurology, Neurovascular Imaging Research Core, UCLA Stroke Center, University of California, Los Angeles (D.S.L.).
Abstract
BACKGROUND AND PURPOSE: The STAIR (Stroke Treatment Academic Industry Roundtable) meeting aims to advance acute stroke therapy development through collaboration between academia, industry, and regulatory institutions. In pursuit of this goal and building on recently available level I evidence of benefit from endovascular therapy (ET) in large vessel occlusion stroke, STAIR IX consensus recommendations were developed that outline priorities for future research in ET. METHODS: Three key directions for advancing the field were identified: (1) development of systems of care for ET in large vessel occlusion stroke, (2) development of therapeutic approaches adjunctive to ET, and (3) exploring clinical benefit of ET in patient population insufficiently studied in recent trials. Methodological issues such as optimal trial design and outcome measures have also been addressed. RESULTS: Development of systems of care strategies should be geared both toward ensuring broad access to ET for eligible patients and toward shortening time to reperfusion to the minimum possible. Adjunctive therapy development includes neuroprotective approaches, adjuvant microcirculatory/collateral enhancing strategies, and periprocedural management. Future research priorities seeking to expand the eligible patient population are to determine benefit of ET in patients presenting beyond conventional time windows, in patients with large baseline ischemic core lesions, and in other important subgroups. CONCLUSIONS: Research priorities in ET for large vessel occlusion stroke are to improve systems of care, investigate effective adjuvant therapies, and explore whether patient eligibility could be expanded.
BACKGROUND AND PURPOSE: The STAIR (Stroke Treatment Academic Industry Roundtable) meeting aims to advance acute stroke therapy development through collaboration between academia, industry, and regulatory institutions. In pursuit of this goal and building on recently available level I evidence of benefit from endovascular therapy (ET) in large vessel occlusion stroke, STAIR IX consensus recommendations were developed that outline priorities for future research in ET. METHODS: Three key directions for advancing the field were identified: (1) development of systems of care for ET in large vessel occlusion stroke, (2) development of therapeutic approaches adjunctive to ET, and (3) exploring clinical benefit of ET in patient population insufficiently studied in recent trials. Methodological issues such as optimal trial design and outcome measures have also been addressed. RESULTS: Development of systems of care strategies should be geared both toward ensuring broad access to ET for eligible patients and toward shortening time to reperfusion to the minimum possible. Adjunctive therapy development includes neuroprotective approaches, adjuvant microcirculatory/collateral enhancing strategies, and periprocedural management. Future research priorities seeking to expand the eligible patient population are to determine benefit of ET in patients presenting beyond conventional time windows, in patients with large baseline ischemic core lesions, and in other important subgroups. CONCLUSIONS: Research priorities in ET for large vessel occlusion stroke are to improve systems of care, investigate effective adjuvant therapies, and explore whether patient eligibility could be expanded.
Authors: Napasri Chaisinanunkul; Opeolu Adeoye; Roger J Lewis; James C Grotta; Joseph Broderick; Tudor G Jovin; Raul G Nogueira; Jordan J Elm; Todd Graves; Scott Berry; Kennedy R Lees; Andrew D Barreto; Jeffrey L Saver Journal: Stroke Date: 2015-07-02 Impact factor: 7.914
Authors: Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan Journal: N Engl J Med Date: 2015-04-17 Impact factor: 91.245
Authors: Jeffrey L Saver; Sidney Starkman; Marc Eckstein; Samuel J Stratton; Franklin D Pratt; Scott Hamilton; Robin Conwit; David S Liebeskind; Gene Sung; Ian Kramer; Gary Moreau; Robert Goldweber; Nerses Sanossian Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel Journal: N Engl J Med Date: 2014-12-17 Impact factor: 91.245
Authors: Bijen Nazliel; Sidney Starkman; David S Liebeskind; Bruce Ovbiagele; Doojin Kim; Nerses Sanossian; Latisha Ali; Brian Buck; Pablo Villablanca; Fernando Vinuela; Gary Duckwiler; Reza Jahan; Jeffrey L Saver Journal: Stroke Date: 2008-06-12 Impact factor: 7.914
Authors: D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk Journal: AJNR Am J Neuroradiol Date: 2018-05-17 Impact factor: 3.825
Authors: Andrea M Herrmann; Stephan Meckel; Matthew J Gounis; Leona Kringe; Edith Motschall; Christoph Mülling; Johannes Boltze Journal: J Cereb Blood Flow Metab Date: 2019-02-07 Impact factor: 6.200
Authors: Thabele M Leslie-Mazwi; Scott Hamilton; Michael Mlynash; Aman B Patel; Lee H Schwamm; Maarten G Lansberg; Michael Marks; Joshua A Hirsch; Gregory W Albers Journal: Stroke Date: 2019-03 Impact factor: 7.914
Authors: William J Ares; Benjamin M Zussman; Cynthia L Kenmuir; Gregory M Weiner; Habibullah Ziayee; Devin Burke; Ashutosh P Jadhav; Tudor G Jovin; Brian T Jankowitz; Bradley A Gross Journal: Interv Neurol Date: 2018-05-31